Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

Vanessa Caceres  |  January 25, 2021

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020diffuse cutaneous systemic sclerosisgiant cell arteritis (GCA)mavrilimumabtocilizumabTofacitinibVIG7734Ziritaxestat

The Psychosocial Toll of COVID-19

Thomas R. Collins  |  January 25, 2021

Experts discussed the heavy toll the pandemic has taken on patients and clinicians, with many patients in need of mental health support and others in need of rehabilitation.

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2020Association of Rheumatology Professionals (ARP)

Smart, Stem Cell-Based Implants May Revolutionize the Treatment of Arthritis

Lara C. Pullen, PhD  |  January 25, 2021

Recent breakthroughs in stem cell-based treatments for arthritis may help delay joint replacement for some patients. Farshid Guilak, PhD, described the methods for creating bioartificial cartilage, its implications for inflammation, disease flare and more.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020jointjoint injectionsmart cellsStem Cells

Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots

Mary Beth Nierengarten  |  January 25, 2021

Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020autoinflammatory diseaseSAPHOSAPHO Syndromesystemic autoinflammatory diseases

Denosumab Promising for Osteolysis after Total Hip Replacement

Marilynn Larkin  |  January 25, 2021

NEW YORK (Reuters Health)—Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial. “Denosumab is already a well-established licensed drug for the indications of osteoporosis and metastatic bone lesions in cancer, and has been shown to be effective in reducing erosions in inflammatory arthritis,” Dr. Mark J.M. Wilkinson of the University…

Filed under:Drug Updates Tagged with:denosumabtotal hip arthroplastytotal hip replacement

Risankizumab May Improve Symptoms of PsA

Michele B. Kaufman, PharmD, BCGP  |  January 21, 2021

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

Filed under:Drug Updates Tagged with:PsAPsoriatic Arthritisrisankizumab

A Pandemic of Psychological Distress Is Upon Us

Tamar Rubinstein, MD, Natoshia Cunningham, PhD, & Andrea Knight, MD, MSCE  |  January 20, 2021

It is nine months into the COVID-19 pandemic in the U.S. and the third wave is upon us, overwhelming hospital systems in many states across the country. But the alarms are being sounded for another looming pandemic as well. As early as spring 2020, significant increases were documented in the prevalence of depression and anxiety,…

Filed under:ConditionsPatient Perspective Tagged with:COVID-19Mental Health

COVID-19 Vaccines: Implications for Rheumatology Practice & Research

Larry Beresford  |  January 19, 2021

In late December, the ACR convened a COVID-19 Vaccine Consortium via a conference call to consider rheumatology’s place in the massive worldwide effort to develop, test, deliver and further study the vaccines promising to bring the historic pandemic under control.

Filed under:Conditions Tagged with:COVID-19COVID-19 Global Rheumatology Alliancepatient carerheumatologistsvaccines

Winter 2021’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  January 19, 2021

New Appointments for Carlos Lozada, MD In the midst of the coronavirus pandemic, Carlos J. Lozada, MD, FACP, FACR, professor of clinical medicine, University of Miami Miller School of Medicine, has expanded his professional and volunteer duties. In May he was appointed chief (interim) of the Division of Rheumatology at the Miller School of Medicine,…

Filed under:AwardsProfiles Tagged with:Dr. Carlos J. LozadaDr. Salahuddin (Dino) KaziMovers & Shakers

PG_Traveler / shutterstock.com

Case Report: Is It Reactive or IBD-Associated Arthritis?

Hanan Ibrahim, MD, Weixia Guo, MD, & Ayad Alkhatib, MD  |  January 19, 2021

Reactive arthritis is classically associated with an infectious etiology, such as Salmonella, Yersinia, Campylobacter, Chlamydia or gonorrhea. Clostridium difficile is a rare, and recently recognized, causative agent for this condition.1 Case Presentation The patient is a 21-year-old man with a past medical history significant for hereditary spherocytosis and Crohn’s disease, complicated by an anorectal fistula,…

Filed under:Axial SpondyloarthritisConditions Tagged with:case reportCrohn's diseaseInfectioninflammatory bowel disease (IBD)Reactive arthritis

  • « Previous Page
  • 1
  • …
  • 77
  • 78
  • 79
  • 80
  • 81
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences